OncLive TV

Faith E. Davies, MD, discusses the research being done in patients with multiple myeloma who are refractory to lenalidomide.

James Weitzman, MD, discusses the challenges of treating patients with penta-refractory multiple myeloma.

Hatim Husain, MD, discusses the evolution of liquid biopsies in lung cancer.

Chris Parker, MD, discusses the rationale for the phase III RADICALS-RT trial in prostate cancer.

Ankit Kansagra, MD, discusses updates with CAR T-cell therapy in multiple myeloma.

Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the FDA approval of tucatinib (Tukysa) in HER2-positive breast cancer.

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses ongoing research with moxetumomab pasudotox-tdfk (Lumoxiti) in patients with hairy cell leukemia (HCL).

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses ongoing research with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Michael L. Grossbard, MD, discusses the phase III DYNAMO study examining the use of duvelisib in the treatment of patients with indolent non-Hodgkin lymphoma.

Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the need for umbrella trials in biliary tract cancer.

Neehar Parikh, MD, discusses criteria for determining transplant eligibility in hepatocellular carcinoma.

Michael A. Choti, MD, discusses the role of upfront surgery in pancreatic adenocarcinoma.

Robert G. Uzzo, MD, MBA, FACS, shares efforts to improve cancer care amidst the COVID-19 crisis.

Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

Kathryn E. Hudson, MD, discusses the utility of liquid biopsy in lung cancer.

Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.

Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.

Corey S. Cutler, MD, MPH, FRCPC, discusses some of the novel preventive strategies against graft-versus-host disease.

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.

Amanda Nickles Fader, MD, discusses the rationale for utilizing HER2/neu as a target in uterine serous carcinoma.

Manish A. Shah, MD, discusses an optimal sequencing strategy in gastroesophageal cancer.

Balazs Halmos, MD, MS, provides insight into how his institution continues to adapt in response to the COVID-19 crisis.

Ibrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.

David Morris, MD, FACS, discusses overall survival data with apalutamide in prostate cancer.